Recently added articles from Formulary:
New molecular entities
Feb 01, 2009; ... Savella Milnacipran FOREST/CYPRESS Selective noreplnephrlne and serotonin reuptake Inhibitor approved for the management of flbromyalgla Milnacipran is a selective norepinephrine and serotonin reuptake inhibitor that inhibits norepinephrine uptake with greater ...
FDA actions in brief
Feb 01, 2009; ... Gadofosveset (Vasovlst, Epix) was approved for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease. Fospropofol injection (Lusedra, Eisai) was approved for monitored anesthesia care sedation in adult patients undergoing diagnostic ...
Dronedarone
Feb 01, 2009; ... An antiarrhythmic agent for the management of atrial fibrillation and atrial flutter Abstract Atrial fibrillation (AF) is a major cause of morbidity and mortality and affects approximately 2.5 million people in the United States. Patients suffering from AF have an increased risk ...
Review of antiretroviral agents for the treatment of HIV infection
Feb 01, 2009; ... Abstract Research into the treatment of HIV infection has resulted in the development of 5 antiretroviral (ARV) drug classes: entry inhibitors, including fusion inhibitors and chemokine coreceptor (CCR) inhibitors; nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs); ...
Healthcare reform requires a hard look at drug costs and savings
Feb 01, 2009; ... FEDERAL AND STATE GOVERNMENT ACTIONS AND THEIR IMPACT ON DRUG DECISION-MAKERS Among members of the new administration, congressional leaders, payors, and providers, many are eager to transform the nation's healthcare system to curb unnecessary spending and make coverage more fair and ...
Preventable medication errors: Look-alike/sound-alike mix-ups
Feb 01, 2009; ... HOW HIGH-TECH ADVANCES AND APPLICATIONS ARE IMPACTING HEALTH-SYSTEM AND MANAGED-CARE PHARMACY Confusing drug names, or "look-alike/ sound-alike names" (LASAs), are among the most common reasons for medication errors worldwide. In 2007, The Joint Commission and the World Health ...
Pipeline preview
Jan 01, 2009; ... Complete response * Ceftobiprole (Johnson & Johnson) for the treatment of complicated skin and skin-structure infections, including diabetic foot infections * Oblimersen (Qenasense, Genta) in combination with chemotherapy for the treatment of chronic lymphocytic ...
First-time generic approvals
Jan 01, 2009; ... Rocuronium injection, 50 mg/5 mL (equiv to Zemuron injection) GENERAMEDIX, HOSPIRA, ...
New molecular entity
Jan 01, 2009; ... Promacta Eltrombopag GLAXOSMITHKLINE TPO receptor agonist approved for the treatment of thrombocytopenia in patients with chronic ITP Eltrombopag is a thrombopoietin (TPO) receptor agonist that initiates signaling cascades by binding to the transmembrane domain of ...
actions in brief
Jan 01, 2009; ... Rufinamide (Banzel, Eisai) was approved for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children aged ≥4 years and adults. Tapentadol immediate-release tablets (Johnson & Johnson) were approved for the relief of moderateto-severe acute pain ...
Sugammadex: A selective relaxant binding agent for neuromuscular block reversal
Jan 01, 2009; ... Abstract Neuromuscular block (NMB) drugs are used to facilitate endotracheal intubation for mechanical ventilation and to provide muscle relaxation in the operating room and intensive care unit. To decrease the risk for postoperative residual paralysis, NMB is reversed at the end of ...
Outpatient pharmacologic management of ACS using antiplatelet therapy: A review of recent guidelines and agents in the pipeline
Jan 01, 2009; ... Abstract Acute coronary syndrome (ACS) encompasses a series of heart conditions associated with myocardial ischemia. Three conditions are classified broadly as ACS: ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation MI (NSTEMI), and unstable angina (UA) ....
Pipeline preview
Dec 01, 2008; ... Complete responses * Denileukin diftitox Ontak, Eisai) for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells did not test positive for the CD25 component of the interleukin-2 receptor * Controlled-release hydrocodone plus ...
New molecular entitles
Dec 01, 2008; ... Rapaflo Silodosin WATSON Alpha-blocker approved for the treatment of BPH Silodosin is a selective alpha- 1 adrenergic receptor antagonist. By blocking these receptors, silodosin causes the smooth muscle in the human prostate, bladder base, bladder neck, prostatic ...
First-time generic approvals
Dec 01, 2008; ... Levetiracetam tablets, 250, 500, and 750 mg (equiv to Keppra tablets) MYLAN Dorzolamide/timolol ophthalmic solution, 2% (base)/0.5% (base) (equiv to ...
actions in brief
Dec 01, 2008; ... FDA Antihemophilic factor (recombinant) (Kogenate FS, Bayer) was approved to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged <16 years with severe hemophilia A and with no pre-existing joint damage. Bendamustine for injection (Treanda, ...
New biologic
Dec 01, 2008; ... Cinryze C1 inhibitor (human) VlROPHARMA C1 Inhibitor approved for prophylaxis of angioedema attacks in patients with HAE This agent is a preparation of C1 inhibitor that is derived from human plasma. C1 inhibitor regulates the activation of the complement and ...
Preferential listing of a PPI: Compliance with policy in a Canadian military population
Dec 01, 2008; ... Abstract Preferential listing of a single drug is a common strategy for controlling costs within a drug class. In 2003, the Canadian Forces (CF) drug benefit plan used preferential listing to control costs associated with proton pump inhibitors (PPIs). However, significant expenditures ...
Clinical news updates from the 2008 American Heart Association Scientific Sessions
Dec 01, 2008; ... The 2008 American Heart Association (AHA) Scientific Sessions took place November 8 to 12, 2008, in New Orleans, Louisiana. Among the new data presented were the results of Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), a ...
Bevacizumab associated with increased risk of venous thromboembolism
Dec 01, 2008; ... FROM THE LITERATURE Treatment with bevacizumab is associated with a significantly increased risk of venous thromboembolism, according to a meta-analysis published in the Journal of the American Medical Association. The risk of both all-grade and high-grade venous thromboembolism was ...